23andMe
Tracked across 1 events · 14 articles · First seen Apr 08, 2026 · Last active Apr 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. This research, published in Nature, leverages data from 27,885 individuals and provides direct evidence that genetic variations influence responses to GLP-1 medications. The company has also released a new report, 'GLP-1 Medications Weight Loss and Nausea', to members of its Total Health service, offering personalized insights based on these findings.
Apr 08, 2026 · 14 articles
100
23andMe published a study identifying genetic predictors for GLP-1 efficacy and side effects Nature (journal)23andMe Identifies GLP-1...
90
23andMe released a new report 'GLP-1 Medications Weight Loss and Nausea'23andMe Identifies GLP-1...
Adam Auton
Vice President of Human Genetics
↔
23andMe
Adam Auton is the Vice President of Human Genetics at 23andMe Research Institute
Noura Abul-Husn
Chief Medical Officer
↔
23andMe
Noura Abul-Husn is the Chief Medical Officer at the 23andMe Research Institute.
NEWSDESK
Track 23andMe live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard